Key result
Cyclin-dependent kinase 4/6 inhibitors were associated with an increased risk of venous thromboembolism (ROR 2.78; 95% CI 2.64-2.92), with specific agents showing varying thromboembolic profiles.
Why the study?
Thrombosis is the second leading cause of mortality in cancer patients, and the study aimed to investigate the association between cyclin-dependent kinase 4 and 6 inhibitors and thrombosis.
Do cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) increase the risk of thromboembolism in cancer patients?
Systematic Review
Do cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) increase the risk of thromboembolism in cancer patients?
Odds Ratio: 2.78 (95% CI 2.64–2.92)
CDK4/6 inhibitors are associated with an increased risk of venous thromboembolism, highlighting the need for thrombotic risk assessment in cancer patients receiving these therapies.
BACKGROUND: Thrombosis is the second leading cause of mortality in cancer patients. This study aimed to investigate the association between cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) and thrombosis. RESEARCH DESIGN AND METHODS: A retrospective pharmacovigilance analysis based on real-world data combined with a systematic review was used to explore the thrombotic risk profiles of CDK4/6i. The study has been registered with Prospero (CRD42021284218). RESULT: In the pharmacovigilance analysis, CDK4/6i showed a higher rate of reported venous thromboembolism (VTE) (ROR = 2.78, 95% CI = 2.64-2.92), with the highest signal for trilaciclib (ROR = 27.55, 95% CI = 13.43-56.52) but only 9 cases, followed by abemaciclib (ROR = 3.73, 95% CI = 3.19-4.37). For arterial thromboembolism (ATE), only ribociclib increased the reporting rate (ROR = 2.14, 95% CI = 1.91-2.41). In the meta-analysis, palbociclib, abemaciclib, and trilaciclib all increased the risk of VTE (OR = 2.23, 3.17, and 3.90). In the subgroup analysis, only abemaciclib increased the risk of ATE (OR = 2.11, 95% CI = 1.12-3.99) . CONCLUSIONS: CDK4/6i had different profiles of thromboembolism. Palbociclib, abemaciclib, or trilaciclib increased the risk of VTE. Ribociclib and abemaciclib showed a weak association with the risk of ATE.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2023) conducted a systematic review in Cancer. Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) was evaluated on Venous thromboembolism (VTE) (ROR 2.78, 95% CI 2.64-2.92). Cyclin-dependent kinase 4/6 inhibitors were associated with an increased risk of venous thromboembolism (ROR 2.78; 95% CI 2.64-2.92), with specific agents showing varying thromboembolic profiles.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: